Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D4ME2Z
|
|||
| Drug Name |
NGM621
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Geographic atrophy [ICD-11: 9B75] | Phase 2 | [1] | |
| Company |
ngmbio
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04465955) A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD). U.S.National Institutes of Health. | |||
| REF 2 | Inhibition of Complement Factor 3 in Geographic Atrophy with NGM621: Phase 1 Dose-Escalation Study Results. Am J Ophthalmol. 2022 Mar;235:131-142. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.